Tools and resources
3 Summary of NICE recommendations
NICE assessed the UroLift system for treating lower urinary tract symptoms of BPH as an alternative to current standard surgical interventions such as TURP and HoLEP.
The case for adoption is supported by the evidence. The UroLift system relieves lower urinary tract symptoms while avoiding the risk to sexual function associated with TURP and HoLEP.
The UroLift system should be considered for use in a day‑case setting, where savings can best be realised in men with lower urinary tract symptoms of BPH who are aged 50 years and older and who have a prostate of less than 100 ml without an obstructing middle lobe. The primary drivers in the costing model were the cost of each implant and the number of implants used per treatment.
This page was last updated: 27 April 2017